Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[4-(3-Aminomethyl-phenyl)-piperidin-1-YL]-(5-phentethyl-pyridin–3-YL)-methanone is an experimental small molecule belonging to the phenylpiperidine class. It has been studied as a ligand and inhibitor for human beta tryptase, a serine protease involved in allergic and inflammatory responses. Structural studies have shown it can bind to beta tryptase, potentially acting as a monomeric or dimeric inhibitor by bridging adjacent active sites of the enzyme. The compound has not been approved for any indication and remains at the experimental stage, with no clinical trials reported beyond preclinical research[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [4-(3-aminomethyl-phenyl)-piperidin-1-yl]-(5-phenethyl-pyridin-3-yl)-methanone.